Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenue, net | $364,252 | $212,802 | $675,589 | $350,052 |
| Operating expenses: | ||||
| Cost of sales | 40,007 | 9,065 | 66,854 | 13,578 |
| Research and development | 91,178 | 54,081 | 199,870 | 98,253 |
| Selling, general and administrative | 289,375 | 196,858 | 557,896 | 364,734 |
| Total operating expenses | 420,560 | 260,004 | 824,620 | 476,565 |
| Loss from operations | (56,308) | (47,202) | (149,031) | (126,513) |
| Interest income | 7,104 | 8,227 | 15,347 | 17,597 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s R&D?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported R&D of $91.18M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s R&D changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s R&D increased by 68.6% year-over-year, from $54.08M to $91.18M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s R&D?
- Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s R&D has grown at a 17.3% compound annual growth rate (CAGR), from $205.16M to $388.53M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude